Skip to main content

Fiscal Wizard · Single-issue tearsheet

KRYS / Jun 22, 2026 Run #7605

KRYS

Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Composite verdict

A 84.5 / 100
Bullish setup · Trend Following 15 drivers · 3 gates blocking
  • Rate of Change
  • Chaikin Money Flow
  • ADX DI Cross
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 12th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 22 signals0% Bear
Momentum Bullish 99Mean-reversion Neutral 51

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -85%
Asset value $41.37Earnings power value $64.72Price $348.06

Priced above its no-growth earnings power value ($64.72/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

69.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
Earnings Yield 0
OCF to Net Income 96
Inventory Turnover 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Rate of Change, Chaikin Money Flow, ADX DI Cross); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 89
Parabolic SAR Flip 87
Chaikin Money Flow 86

Risk Gates

3 blocking 6 caution

3 guards active, 17 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for KRYS.